Key points are not available for this paper at this time.
Design
Review
Clinicians should monitor for serotonin syndrome with serotonergic agents; this review leaves open precise incidence and management data.
The serotonin syndrome is characterized by features of neuromuscular hyperactivity, autonomic instability, and alteration of mental status. It is the clinical manifestation of serotonin toxicity resulting from the combination of drugs that cause increased intra-synaptic serotonin activity. Antidepressant drugs and drugs of abuse are well-recognized causes. The syndrome can also be triggered by a variety of other drugs with serotonergic effects, including opioids, appetite-suppressant drugs, herbal products and drugs used for anxiety, migraine, and Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Ruben Thanacoody (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: